atakan BrainStorm ( NASDAQ: BCLI ) announces the appointment of Hartoun Hartounian as its new EVP and COO, effective as of June 18, 2024. The appointment completes executive readiness for the registrational phase 3b ALS study launch. Hartounian, with 32 years of experience in the biopharmaceutical industry, founded BioCentriq, a full-service, collaborative, revenue-generating CDMO company for cell and gene therapy, focusing on all stages of process development and clinical manufacturing.
He most recently served as President, CEO, and a member of the board at BioCentriq. Shares in the company were down 10.4% in premarket trading on Thursday.
More on BrainStorm: BrainStorm Cell Therapeutics promotes Bob Dagher to Chief Medical Officer BrainStorm gains as FDA OKs Phase 3 trial design for ALS therapy Seeking Alpha’s Quant Rating on BrainStorm Cell Therapeutics Historical earnings data for BrainStorm Cell Therapeutics Financial information for BrainStorm Cell Therapeutics.